Eriksen Jaran, Ovesjö Marie-Louise, Vallin Martina, Juhasz-Haverinen Maria, Andersén-Karlsson Eva, Ateva Kristina, Gustafsson Lars L, Jirlow Malena, Bastholm-Rahmner Pia
Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Pharmacology, Karolinska University Hospital, 141 86, Stockholm, Sweden.
Eur J Clin Pharmacol. 2018 Jan;74(1):131-138. doi: 10.1007/s00228-017-2354-8. Epub 2017 Oct 23.
Inappropriate use of medicines causes increased morbidity, mortality, adverse drug reactions, therapeutic failures and drug resistance as well as wastes valuable resources. Evidence-based cost-effective treatment recommendations of essential medicines are a way of avoiding these. We assessed primary care prescribers' knowledge about and perceptions of an essential medicines formulary, as well as the reasons for adhering to the recommendations.
We conducted a web based questionnaire survey targeting all physicians working in the primary healthcare of the Stockholm healthcare region (2.3 million inhabitants), regarding the knowledge of, attitudes to and usefulness of the essential medicines formulary of the Stockholm Drug and Therapeutics Committee, the so-called Wise List.
Of the 1862 physicians reached by our e-mail invitations, 526 (28%) participated in the survey. All but one respondent knew of the formulary, and 72% used it at least once a week when prescribing. The main reason for using the formulary was evidence-based prescribing; 97% trusted the guidelines, and almost all (98%) found the content easy to understand. At the same time, many prescribers thought that the annual changes of some recommendations were too frequent, and some felt that a national formulary would increase its trustworthiness.
We found that the essential medicines formulary was widely used and trusted by the prescribers. The high uptake of the treatment recommendations could be due to the Stockholm Drug and Therapeutics Committee's transparent process for developing recommendations involving respected experts and clinicians using strict criteria for handling potential conflicts of interest, feedback to prescribers, continuous medical education and minor financial incentives.
药物的不当使用会导致发病率上升、死亡率增加、药物不良反应、治疗失败和耐药性,还会浪费宝贵的资源。基于证据的基本药物成本效益治疗建议是避免这些问题的一种方式。我们评估了初级保健开处方者对基本药物处方集的了解和看法,以及遵循这些建议的原因。
我们针对斯德哥尔摩医疗保健地区(230万居民)初级医疗保健工作的所有医生开展了一项基于网络的问卷调查,内容涉及对斯德哥尔摩药物与治疗委员会基本药物处方集(即所谓的明智清单)的了解、态度和实用性。
在我们通过电子邮件邀请的1862名医生中,有526名(28%)参与了调查。除一名受访者外,所有受访者都知道该处方集,72%的人在开处方时每周至少使用一次。使用该处方集的主要原因是基于证据的开处方;97%的人信任这些指南,几乎所有人(98%)都觉得内容易于理解。与此同时,许多开处方者认为一些建议的年度变化过于频繁,一些人觉得国家处方集会增加其可信度。
我们发现基本药物处方集被开处方者广泛使用并信任。治疗建议的高采用率可能归因于斯德哥尔摩药物与治疗委员会制定建议的透明过程,该过程涉及受尊敬的专家和临床医生,使用严格的标准处理潜在的利益冲突,向开处方者反馈,持续医学教育以及少量经济激励。